Division of Rheumatology, Department of Internal Medicine, Marmara University, Turkey.
Division of Rheumatology, Department of Internal Medicine, Marmara University, Turkey.
Semin Arthritis Rheum. 2020 Aug;50(4):586-591. doi: 10.1016/j.semarthrit.2020.04.003. Epub 2020 May 14.
To assess the progression and the factors associated with damage in Takayasu's arteritis (TAK) patients during routine follow-up.
Patients diagnosed with TAK and had >6 months follow-up were enrolled in this study retrospectively. Takayasu's arteritis damage score (TADS) and vasculitis damage index (VDI) were determined at diagnosis and at the end of the follow-up and variables associated with damage scores were assessed.
One-hundred fourteen patients (F/M: 101/13) were included in the study. The mean age at diagnosis, median symptom duration at baseline visit and mean follow-up duration were 35.3±13.3 years, 12 (0-360) months and 76.9±51.4 months, respectively. Median VDI score was 4.0 (1-8) and median TADS score was 7.0 (1-15) at baseline assessment. At the end of the follow-up, median VDI score increased to 5.0 (1-17) and TADS score to 8.0 (1-19). The median number of disease-related items were higher in TADS (8 items vs 4 items). At least one new corticosteroid (CS)-related damage item occurred in 35 patients (31%). Age at symptom-onset and cumulative CS doses were predictor factors for higher VDI score (≥5), whereas age at symptom-onset and disease duration were associated with increase in TADS (≥8). Gender and number of relapses were not associated with damage scores.
Damage assessment with VDI seems to capture treatment-related damage better, whereas TADS provides some additional information on disease-related damage in Takayasu's arteritis. Older age at symptom onset, disease duration and cumulative CS dose were associated with higher damage scores. The relapse frequency did not influence the damage level in our routine-follow-up of TAK patients.
评估大动脉炎(TAK)患者在常规随访期间的进展情况及其与损伤相关的因素。
本研究回顾性纳入了诊断为 TAK 且随访时间>6 个月的患者。在诊断时和随访结束时,确定 Takayasu 动脉炎损伤评分(TADS)和血管炎损伤指数(VDI),并评估与损伤评分相关的变量。
本研究纳入了 114 例患者(F/M:101/13)。诊断时的平均年龄、基线访视时的中位症状持续时间和平均随访时间分别为 35.3±13.3 岁、12(0-360)个月和 76.9±51.4 个月。基线评估时的中位 VDI 评分为 4.0(1-8),中位 TADS 评分为 7.0(1-15)。随访结束时,中位 VDI 评分增加至 5.0(1-17),TADS 评分增加至 8.0(1-19)。TADS 中疾病相关项目的中位数更多(8 项 vs 4 项)。35 例患者(31%)至少出现了 1 项新的皮质类固醇(CS)相关损伤项目。发病年龄和累积 CS 剂量是 VDI 评分(≥5)的预测因素,而发病年龄和疾病持续时间与 TADS(≥8)的增加相关。性别和复发次数与损伤评分无关。
VDI 进行损伤评估似乎能更好地捕捉治疗相关的损伤,而 TADS 则提供了大动脉炎疾病相关损伤的一些额外信息。发病年龄较大、疾病持续时间和累积 CS 剂量与较高的损伤评分相关。在我们对 TAK 患者的常规随访中,复发频率并未影响损伤水平。